综述

登革病毒E蛋白结构域Ⅲ疫苗研究进展

  • 孟胜利 孙燕
展开
  • 430060 武汉生物制品研究所狂犬病疫苗室(孟胜利);430074 中南民族大学武汉神经科学和神经工程研究所(孙燕)

网络出版日期: 2025-08-16

Current status in research of dengue vaccine candidates based on domain Ⅲ of E protein

Expand
  • *Department of Rabies Vaccine, Wuhan Institute of Biological Products, Wuhan 430060, China

Online published: 2025-08-16

摘要

理想的登革热疫苗应该是副作用小,可以诱导持久的抵抗4个血清型登革病毒感染的保护作用,并且价格合适。登革病毒E蛋白结构域Ⅲ介导受体连接作用并可诱导特异性中和抗体。此文主要介绍利用E蛋白结构域Ⅲ来开发登革热疫苗的研究进展。

本文引用格式

孟胜利 孙燕 . 登革病毒E蛋白结构域Ⅲ疫苗研究进展[J]. 国际生物制品学杂志, 2011 , 34(2) : 72 -76 . DOI: 10.3760/cma.j.issn.1673-4211.2011.02.005

Abstract

 The ideal dengue vaccines should be low reactogenic, induce life-long protection against infection with any of the four serotypes of dengue viruses, and be affordable. The envelope protein domain III of dengue virus has been implicated in receptor binding, and is also the target of specific neutralizing antibodies. In this article, the current state of knowledge on vaccine candidates based on domain III is reviewed.
文章导航

/